Pegloticase
Brand name: Krystexxa
Rank #245 of 500 drugs by total cost
$52.2M
Total Cost
1,134
Total Claims
$52.2M
Total Cost
59
Prescribers
$46K
Cost per Claim
26
Beneficiaries
1,134
30-Day Fills
$885K
Avg Cost/Provider
19
Avg Claims/Provider
About Pegloticase
Pegloticase (sold as Krystexxa) was prescribed 1,134 times by 59 Medicare Part D providers in 2023, costing the program $52.2M. At $46K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 242 | Oxybutynin Chloride (Oxybutynin Chloride Er) | $53.4M | 1,872,901 |
| 243 | Raltegravir Potassium (Isentress) | $53.0M | 25,491 |
| 244 | Belumosudil Mesylate (Rezurock) | $52.3M | 2,280 |
| 245 | Pegloticase (Krystexxa) | $52.2M | 1,134 |
| 246 | Estrogens, Conjugated (Premarin) | $52.0M | 130,171 |
| 247 | Ranolazine (Ranolazine Er) | $51.6M | 381,631 |
| 248 | Epoetin Alfa (Epogen) | $51.4M | 34,952 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology